Member news

Myricx Bio announces that it has been awarded the Cancer Research Horizons Start-Up Achievement Recognition Award for 2025, which it received at a ceremony in London last night.

Cellular Origins, the Cell and Gene Therapy Catapult and Resolution Therapeutics today announce the formation of a consortium which has been awarded a cross-industry Smart Grant of £1 million from Innovate UK, the UK’s national innovation agency.

Coulter Partners successfully completed a search assignment for QBiotics Group Limited (QBiotics) and announces the placement of Sergio Duchini as Non-executive Director.

PIR International spoke with the Chief Executive Officer of Muna Therapeutics, Rita Balice-Gordon, as part of their BioLeader interview series.

Cancer Research Horizons, the innovation arm of Cancer Research UK, has announced the winners of its third Innovation and Entrepreneurship Awards.

The BioIndustry Association (BIA) today announces that Canary Wharf Group (CWG) and Kadans Science Partner (Kadans) have joined as annual supporters. This is a move that speaks to the strength of BIA and the vitality of the UK life sciences ecosystem.

Today, the British Business Bank has announced a new £400 million Investor Pathways Capital initiative, which will support diverse and emerging fund managers across the economy and make it easier for new entrants, particularly those from underrepresented groups, to break into venture capital.

Coulter Partners successfully completed a search assignment for Biomia and is pleased to announce the placement of Frederick Westhorpe, PhD as Chief Scientific Officer (CSO).

Coulter Partners successfully completed search assignments for Augustine Therapeutics NV.

Hosted at West Road Concert Hall in Cambridge, the Symposium brings together leading minds from academia and industry to showcase cutting-edge research and its translation into novel therapeutics.

Their vanguard, breakthrough proteomics platform technology unlocks full-length protein sequencing and characterisation, accelerating drug development and diagnostics.

Rinri Therapeutics is focused on transforming sensorineural hearing loss (SNHL) with regenerative cell therapy, providing new therapeutic options for the treatment of this major global unmet medical need.

Cancer Research Horizons, the innovation arm of Cancer Research UK, has appointed its first Clinical Advisory Board to provide strategic guidance on the development of novel cancer therapeutics emerging from its drug discovery division, Therapeutic Innovation.

Laverock Therapeutics closes additional seed funding round, bringing total raised to more than £20 million.

OutSee, announced it has secured £1.8 million in seed funding, led by Ahren Innovation Capital and with additional investment from Kadmos Capital, Empirical Ventures and Panacea Ventures.

Two-part clinical study programme to evaluate change in lean and fat mass in patients receiving two different doses of S-pindolol benzoate whilst 1) receiving the GLP-1 agonist semaglutide; and 2) after cessation of semaglutide treatment; Initial proof-of-concept data expected in second half of 2026

The average size of artificial intelligence (AI) deals was significantly higher than deals across the wider UK equity market in 2024, underlining the continued focus on the sector, reveals the British Business Bank’s annual Small Business Equity Tracker, published today.

Gastronomica, Pioneer Group’s cutting-edge food tech hub, was crowned winner of the Innovative Workplace Design award at the Property Week and Construction News Life Sciences & Research Clusters Awards.

Brainomix and 3DR Labs announced a new strategic partnership to support acute stroke care in the US through the clinically validated and FDA-cleared Brainomix 360 Stroke.

Revolutionary network of national scanners accelerates diagnosis and drug development to deliver patient benefit